Abstract
Efavirenz is an antiretroviral medicine generally used to treat HIV infection. As a non-nucleoside reverse transcriptase inhibitor (NNRTI), it inhibits the replication of the contagion. Efavirenz is well absorbed when taken orally, reaching peak tube attention within 3-5 hours. Its long elimination half-life of 52-76 hours allows for formerly diurnal dosing and improves patient compliance. Efavirenz is primarily metabolized in the liver by cytochrome P450 enzymes, particularly CYP2B6 and CYP3A4, and undergoes expansive hepatic metabolism to form inactive metabolites. The medicine is substantially excreted in the feces, with a small quantum excreted in the urine. Efavirenz may interact with other medicines and substances due to its influence on the exertion of CYP3A4 and its metabolism through CYP2B6. Medicine-medicine relations should be precisely considered to avoid compromising the efficacity and safety of co-administered medicines. There are certain contraindications to the use of Efavirenz. People with known acuity to the medicine or its factors shouldn’t take Efavirenz. Efavirenz isn’t recommended for pregnant women due to the increased threat of fetal neural tube blights. Effective contraception is essential for women of travail eventually taking Efavirenz. In conclusion, Efavirenz is a precious formerly-diurnal dosing antiretroviral medicine that supports patient compliance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research Journal of Pharmacology and Pharmacodynamics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
